| Accession |
PRJCA016088 |
| Title |
APTN-SIMM-PK-II A randomized, double-blind, parallel-controlled, multicenter Phase II clinical study of Apatinib mesylate tablets in the treatment of advanced gastric cancer |
| Relevance |
Medical |
| Data types |
clinical information,metabolic data,etc
|
| Organisms |
Homo sapiens
|
| Description |
In this study, patients with advanced gastric cancer were selected as subjects. Subjects took a certain dose of Apatinib mesylate orally for 28 consecutive days, and different administration methods of Apatinib were investigated (qd: 850mg, once-a-day administration group; bid: 425mg, twice daily administration group) on the expression of biological markers VEGF and VEGF-R2 in serum of patients with advanced gastric cancer compared with placebo group. |
| Sample scope |
Multiisolate |
| Release date |
2023-04-06 |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| NA
|
NA
|
NA
|
|
|
|
| Submitter |
luchongyang
chongyang
lu (chongyang.lu@hengrui.com)
|
| Organization |
Jiangsu Hengrui Pharmaceutical Co. LTD |
| Submission date |
2023-04-06 |
